Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 3
1996 4
1997 1
1998 2
1999 2
2000 2
2001 2
2002 2
2003 1
2004 1
2005 1
2007 2
2008 2
2009 1
2010 3
2011 3
2012 3
2013 1
2014 2
2015 3
2016 3
2017 6
2018 10
2019 7
2020 5
2021 2
2022 3
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Current approaches for the treatment of multiple myeloma.
Watanabe R, Tokuhira M, Kizaki M. Watanabe R, et al. Among authors: tokuhira m. Int J Hematol. 2013 Mar;97(3):333-44. doi: 10.1007/s12185-013-1294-z. Epub 2013 Mar 10. Int J Hematol. 2013. PMID: 23475758 Review.
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T. Tsuchiya S, et al. Among authors: tokuhira m. Intern Med. 2023 Nov 15;62(22):3299-3303. doi: 10.2169/internalmedicine.1611-23. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005261 Free PMC article.
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Nishiyama-Fujita Y, et al. Among authors: tokuhira m. Ann Med. 2022 Dec;54(1):1244-1254. doi: 10.1080/07853890.2022.2069280. Ann Med. 2022. PMID: 35486442 Free PMC article.
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: tokuhira m. Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8. Int J Hematol. 2024. PMID: 38587692
75 results